WO2013126173A1 - Safety syringe and safety dose combination kit - Google Patents
Safety syringe and safety dose combination kit Download PDFInfo
- Publication number
- WO2013126173A1 WO2013126173A1 PCT/US2013/022926 US2013022926W WO2013126173A1 WO 2013126173 A1 WO2013126173 A1 WO 2013126173A1 US 2013022926 W US2013022926 W US 2013022926W WO 2013126173 A1 WO2013126173 A1 WO 2013126173A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syringe
- medication
- dosage
- patient
- weight
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims abstract description 294
- 229940079593 drug Drugs 0.000 claims abstract description 292
- 238000005259 measurement Methods 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000004364 calculation method Methods 0.000 claims abstract description 53
- 239000003085 diluting agent Substances 0.000 claims description 44
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 239000003708 ampul Substances 0.000 claims description 25
- 230000000875 corresponding effect Effects 0.000 claims description 19
- 230000002596 correlated effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002483 medication Methods 0.000 abstract description 14
- 238000013461 design Methods 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- 238000012795 verification Methods 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 208000036647 Medication errors Diseases 0.000 description 6
- 229940126534 drug product Drugs 0.000 description 6
- 229940071643 prefilled syringe Drugs 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000037004 Myoclonic-astatic epilepsy Diseases 0.000 description 2
- 206010057362 Underdose Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- -1 for example Polymers 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000032802 Drug name confusion Diseases 0.000 description 1
- 208000036628 Incorrect route of drug administration Diseases 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
Definitions
- the present invention is related, generally, to the field of medicine delivery apparatuses, systems and methods. More specifically, embodiments of the present invention are related to articles, systems, and methods that are used in the administration of medications to patients, particularly via syringe.
- MAAE Medical Administered Errors
- the United States Food and Drug Administration evaluated reports of fatal medication errors that it received from 1993 to 1998 and found that the most common types of errors occurred as the result of the injection of medication. These errors included: the administration of an improper dose (41 percent); the administration of the wrong medication (16 percent); and the use of the wrong route of administration (16 percent).
- the FDA also notes in a study that medication errors injure approximately 1.3 million people annually in the US alone. Children are considered the most vulnerable population because their smaller body masses make them more sensitive to overdoses or underdoses of medication, which could result in the ineffective treatment of the underlying condition, adverse reaction, illness, and even death.
- Embodiments of the present invention are directed to new and improved apparatuses, kits, designs and methods for administering medication through
- pharmaceutical syringes or other apparatuses designed to increase efficiency, substantially eliminate multiple procedural user steps, improve patient-specific precise dosing and to substantially prevent or eliminate MAE, while significantly reducing the overall costs associated with the administration of medicine.
- the present invention is directed to a method for extracting a medication comprising the steps of providing a medication in a medication container, providing a first syringe, with the first syringe comprising an indicia relating to a recommended dosage of the medication.
- the container may be a vial, an ampoule, or any suitable medicinal container.
- the need for calculations or correlations of a medication dosage to a patient's weight or body surface area are obviated, as a portion of the first syringe is presented to or delivered into the container, and the first syringe is filled to a recommended dosage with the injectable medication, and once again obviating the need for calculations or correlations of a medication dosage to a patient's weight or body surface area.
- the injectable medication is then administered into a patient.
- the dosage is indicated on the syringe in volumetric dosage, and preferably, the dosage is indicated in units such as, for example, CC, IU, MG, MCG, and ML to patient weight or body surface area.
- the patient weight or body surface area is indicated in units including, for example, KG, LB, G and m .
- the present invention further comprises the steps of providing a lyophilized or dry-filled composition in the medication container, providing a diluent in a diluent container, and reconstituting the lyophilized or dry filled composition by providing the diluent to the lyophilized or dry-filled composition.
- a preferred method further comprises the steps of providing a diluent container to reconstitute the medication, and wherein the first syringe is volumetrically calibrated with measurement indicia and recommended dosage, providing a second syringe, said second syringe volumetrically calibrated with measurement indicia for the diluent, extracting a correct amount of diluent from the diluent container using the second syringe, injecting the extracted diluent from the second syringe into the medication container, reconstituting the medication; and obviating the need for calculating or correlating the medication, or the syringe to a patient's weight or body surface area.
- a syringe comprising a barrel comprising at least two substantially permanent calibrated measurement indicia, wherein a first indicia comprises a volumetric dosage of a medication that correlates a
- the barrel of the syringe comprises a third or multiple substantially permanent calibrated measurement indicia correlated to a manufacturer's maximum dosage to a patient's weight or patient's BSA.
- the barrel comprises a substantially permanent calibrated measurement indicia correlating to a specific dosage schedule of a specific medication to patient weight.
- desired printed information identifying a medication on a syringe component can exist on one of more of any syringe component including a barrel, a plunger nested within a barrel, and combinations thereof.
- the information includes: medication name, medication strength, medication dosage-to- weight, and combinations thereof.
- the printed information is preferably the name of medication, the strength of medication, medication dosage-to-weight, and combinations thereof.
- the syringe may be pre-filled with a medication, with the syringe comprising a substantially permanently calibrated measurement indicia correlating the dosage of the medication to a patient's weight.
- the plunger is preferably dimensioned to nest within the barrel, and plunger may be permanently calibrated with measurement indicia correlating the dosage of the medication to the patient weight.
- the present disclosure is also directed to a kit comprising a pre -measured volumetrically scaled medication container having a preselected volume and a syringe having a volume capacity substantially equivalent to the preselected volume and a barrel comprising at least two substantially permanent calibrated measurement indicia, wherein a first indicia is a recommended dosage that specifically correlates the recommended dosage to a second substantially permanent measurement indicia for a patient's weight.
- the kit is preferably pre-packaged and tamper-resistant.
- the container is selected from the group including a vial, an ampoule, and combinations thereof.
- the syringe is filled with a volume from the medication container to a maximum calibrated measurement indicia without any calculations or correlations.
- the measurement indicia are calibrated to deliver the correct doses of the recommended dosage of a specific medication to a particular patient weight without any calculations or correlations.
- kits comprising a medication in a medication container and a first syringe corresponding to the medication container, with the medication volume scaled in the medication container to correlate with the first syringe, and the syringe comprising an indicia calibrated to deliver the medication according to a recommended medication dosage to a patient weight or body surface area.
- the present disclosure is directed to a method for delivering medication to a patient via a syringe comprising the steps of providing a medication in a container providing a syringe comprising calibrated measurement indicia and a recommended or maximum dosage of the medication without the need for any calculations or correlations of the medication dosage to the patient's specific weight, correlating the volume of the medication in the container to specifically correlate the medication to calibrated measurement indicia of the syringe, delivering a portion of the syringe into the container and filling the syringe to a recommended dosage of the medication without the need for any calculations or correlations of the medication dosage to the patient's specific weight and administering the medication into a patient.
- the syringe preferably is filled to a recommended or maximum dosage of the medication such that the indicia would correctly administer a recommended dosage-to-weight volume without additional calculations.
- the volume of the syringe is correlated through reducing the interior diameter of the barrel core to provide an enlarged indicia on the syringe for a reduced patient weight range and for better visibility, accuracy, and lower incremental doses for smaller volumes injections.
- the present disclosure relates to a method for extracting a medication from a container comprising the steps of providing a medication in a container, providing a syringe comprising a calibration relating to the medication and featuring a first volumetric indicia for dosage strength and a second indicia relating to a recommended patient weight or body surface area (BSA).
- the calibration does not require any further calculations or correlations of the medication dosage to the patient's specific weight.
- a portion of the syringe is delivered into the container and the syringe is filled to a recommended dosage with the injectable medication without the need for any
- the injectable medication is then administed to the patient via the syringe.
- the present invention substantially eliminates as many sources of human error as possible in the administration of injectable medications by eliminating the user's need to perform separate calculations and correlations without deviating from industry acceptable practices or the instructions for administration issued by the manufacturer of the medication.
- embodiments of the present invention completely remove and eliminate the practices and procedures currently used in the healthcare industry that are responsible for the primary causes of Medical Administered Errors by injectable administration.
- embodiments of the present invention eliminate the procedures, methods, research and verification ordinarily conducted by users through the consolidation of, for example, the correct medication for patient class, the correct diluent(s), syringe(s) and needle(s) for the medication, correlation of the correct diluent(s), syringe and needle for the route of administration of the particular medication, calculation of correct amount of diluent for the medication, as well all calculations necessary to administer the correct drug dosage to the specific patient, etc.
- a syringe is designed and volumetrically calibrated for use with a specific medication within a combinatorial tamper-resistant kit, whereby the syringe is used to load and administer the dosage that the manufacturer recommends for the patient's particular body weight, or body surface area (BSA), solely through its design.
- BSA body surface area
- the syringe's volumetrically calibrated substantially permanent indicia indicate the amount of medication to be administered to a patient of a given weight or more complex patient feature and measurement, such as, for example, body surface area (BSA) measured in m , for ultra-sensitive, precise dosage used in biologies and oncology medications, among others. No additional steps or devices are necessary.
- BSA body surface area
- embodiments of the present invention are directed to a process for extracting an injectable medication by providing a composition to be injected and a syringe comprising recommended and/or maximum dosage-to-weight indicia of the injectable medication.
- the syringe is filled with injectable medication from the container (vial, ampoule, etc.) to a recommended or maximum dosage (based on the body weight of the patient) of the injectable medication without the need for any calculations or correlations of the medication's dosage schedule to the patient's specific weight and administered into the patient.
- a pre-measured, volumetrically calibrated, scaled container that specifically correlates the medication dosage strength and/or volume to the indicia on the syringe within the kit.
- the syringe comprises a barrel bearing at least two permanent calibrated measurement indicia, wherein the first indicia is a recommended dosage that specifically correlates the recommended dosage to a second permanent measurement indicia for a patient's weight.
- the medication may be scaled to individual patient range within the kit correlating to the calibrated syringe indicia for that targeted patient range, provides a precise lower dose calibration scale, reduces the potential severity of an overdose, and also provides for a patient- specific injection range that significantly reduces waste medication left within the container associated by typical industry standard practices.
- Still further embodiments of the present invention are directed to a method for delivering medication to a patient via a syringe by providing a combination kit comprising a medication in a container, and providing a syringe, said syringe comprising calibrated measurement indicia and a recommended or maximum dosage of the medication without the need for any calculations or correlations of the medication dosage to the patient's specific weight or BSA.
- the volume of the medication is calculated in the container to specifically correlate the medication to calibrated measurement indicia of a syringe.
- a portion of the syringe is directed into the container and filled to a
- a further embodiment of the present invention is directed to a method for delivering medication to a patient via a syringe by providing a medication in a container and providing a syringe that bears calibrated measurement indicia for that particular medication that is then calibrated and correlated to another indicia measurement for a recommended and/or maximum dosage to patient weight or BSA of the medication without the need for the user to perform any calculations or correlations of the medication dosage to the patient's specific weight.
- the syringe barrel may be manufactured to have a specific core diameter or other volumetric calibration adjustment to provide enlarged elongated targeted indicia on the syringe for specific patient weight or BSA range, thus providing better visibility, accuracy, and lower incremental calibration doses for smaller volumes injections, such as for neonatals and pediatrics.
- FIGs. 1, 2 and 3 illustrate close-up views of the syringe's indicia and safety re- verification indicators including indicia and indicators that appear on the syringe;
- FIG. 4 is a close-up view of the plunger section of a syringe according to one embodiment of the present invention with permanent identifying destination of the medication for which it is designed and intended for, medication dosage to weight and that the syringe is not to utilized outside of the kit or with any other medication;
- FIG. 5 illustrates the syringes according to embodiments of the present invention with various indicia and the plunger designations, including the name of the medication, dosage of the medication to the weight of the patient, and that the syringe is excusively calibrated to that medication;
- FIG. 6 illustrates an industry standard pre-filled 500 mg vial and 100 mg ampoule that would be used for the injection of 8 kg or less into a pediatric patient and the unused medication that would be wasted if a 5mg/kg dosage were to be administered;
- FIG. 6A illustrates a volumetrically-scaled patient weight range specific pre-filled 40 mg vial or ampuole within the combination kit that would be utilized for the injection of less than 8 kg of medication to a pediatric patient that would result in little or no waste, depending on the patient injection.
- FIG. 6B illustrates a view of the syringe contained within a combination kit of calibrated for a medication strength of 5mg/kg for pediatric range weights of 0.5 to 8.0 kg;
- FIG. 7 illustrates views of a two syringe multi-diluent vial combination kit, where by one syringe can be calibrated and its indicia correlated specifically to the diluent(s) and the withdrawal and introduction of them into the medication for reconstitution.
- the other syringe is calibrated and its indicia correlated specifically for the medication and the withdrawal and administration of the dosage of the medication to individual patient weight or BSA.
- FIG. 7 also illustrates a view of a one syringe, medication and vial diluent combination kit.
- the syringe is calibrated and its indicia correlated specifically for the medication and the withdrawal and administration of the dosage of the medication to individual patient weight or BSA.
- FIG. 7 also illustrates a view of a one syringe, medication and ampoule diluent combination kit, with dual attachable needles for the syringe.
- the syringe is calibrated and its indicia correlated specifically for the medication and the withdrawal and administration of the dosage of the medication to individual patient weight or BSA.
- FIG. 8 illustrates a cross section of the syringe showing the exterior diameter of the barrel in various options available yet the inner barrel calibrated to individual dosage volumes.
- FIGs. 9-10 illustrates a typical small volume injection within a industry standard 3 ml volume syringe and the indicated level of the dosage on the indicia.
- FIG. 10 illustrates a syringe according to embodiments of the present invention; the syringe having the same outer diameter as the 3ml volume syringe of FIG. 9, yet through it calibrated inner barrel offering enhanced visibility as it extends a 1ml volume through the full indicia of the syringe in lower incremental doses for increased precision.
- a syringe or other apparatus for medicinal administration may be designed for use with a specific medication.
- the syringe is preferably clearly and conspicuously labeled to indicate the name of the medication it is intended to administer.
- the syringe bears a calibration scale on one or more of its barrel, its plunger, or other component that is marked in indicia of a patient characteristic, such as, for example, patient weight or body surface area (BSA, measured as m 2 ).
- BSA body surface area
- the syringe's indicia may also provide a maximum calibrated column that correlates to the maximum MCG, CC, IU, MG, ML dosage-to-patient' s particular weight or BSA, (G, KG, LB, m 2 ) utilizing the recommended manufacturer's dosage schedule.
- FIGs. 1-3 illustrate several variations of indicia 100 for embodiments of the present invention.
- Indicia 100 comprises measuring characteristics 101 and graduation markings 102 that correlate and correspond the patient's weight or BSA measures in KG 103, or m 104, or LB or G to the recommended dosage for the patient's weight comprising measuring characteristics MG 107, IU 108 mL 109 or MCG.
- Indicia 100 may also include measuring characteristics 101 and graduation markings 102 that correlate and correspond to the recommended maximum dosage based on the patient's weight 105 or BSA 106. Indicia 100 may also include measuring characters 101 and graduation markings 102 that correspond to the strength (or concentration) 107 of the medication within the dosage. Indicia 100 may also include measuring characters 101 and graduation markings 102 that correspond to the amount of a substance 108 based on the biological activity or effect of the medication within the dosage. Indicia 100 may also comprise measuring characters 101 and graduation markings 102 that correspond to volume 109 of the medication.
- FIG. 4 shows a pre-calibrated syringe 400 comprising a plunger 401, a syringe barrel 402, and a needle 403.
- the syringe barrel 402 comprises measuring indicia 100 corresponding to dosages based on a patient's weight 103 or body surface area (not shown).
- the syringe preferably comprises a gasket 404 located at and attached to one end of plunger 401.
- Gasket 404 is preferably made from rubber or other sterilizable material and may be modified as to be colored or exhibit fluorescent properties in natural light or upon exposure to light outside of the visible spectrum (e.g. ultraviolet light, infrared, etc.) to assist in the visible accuracy obtained in preparing and verifying the dosage per calibration scale.
- FIG. 5 shows examples of pre-calibrated syringes 400.
- the syringe 400 comprises a plunger 401 and a syringe barrel 402 comprising measuring indicia 100 that correlate and correspond medication dosage in MG 107, IU 108, mL 109 or MCG to an individual patient's weight 103 or body surface area (not shown).
- the plunger 401 preferably comprises a clear and conspicuous substantially permanent indication 405 of at least the medication name 406, dosage strength, recommended dosage to weight 408, or weight range 409 or the medication contained in the syringe.
- the syringe provides users with several key visual aids that help to avoid, for example, administration errors in the dosage of the medication, the use of the medication itself, the strength of the medication, etc.
- FIG. 6 shows an industry standard pre-filled (either dry or liquid) 500mg vial 600 and lOOmg ampoule 601 of injectable medication.
- a low dose pediatric or reduced- weight patient dosage injection of 5mg per kg for an 8kg patient would require 40mg 603 and 608.
- FIG. 6 shows an industry standard pre-filled (either dry or liquid) 500mg vial 600 and lOOmg ampoule 601 of injectable medication.
- a low dose pediatric or reduced- weight patient dosage injection of 5mg per kg for an 8kg patient would require 40mg 603 and 608.
- 6A illustrates a volumetrically-scaled patient weight range pre-filled 40mg 606 in vial 604 or ampoule 605 within the combination kit that would be used for the injection of the medication to, for example, the 8kg or less pediatric patient that would result in a minimum 460mg of the 500mg vial not being wasted (the volume shown as 602) or in a minimum of 60mg of the lOOmg ampoule not being wasted (the volume shown as 607) as would otherwise occur. (See FIG. 6).
- FIG. 6B shows a volumetrically calibrated syringe 400 to specifically correlate to the medication with the kit, and volume-scaled small dose patient range 606 to solely correlate with the vial or ampoule medication dosage strength of 5 mg/kg for pediatric range weights of from about 0.5 to about 8.0 kg.
- FIG. 7 illustrates variations of a pre-packed kit 700 contemplated by embodiments of the present invention.
- the pre-packaged kits 700 consist of a single unit, preferably tamper-resistant container packaged as a "blister pack” or as a “clamshell", as would be readily understood in the packaging field.
- packaging 701 is preferably made from sterilizable materials including a plastic such as, for example, high density polyethylene (HDPE), polyethylene terephthalate (PET), polycarbonate, etc.
- the kit comprises pre- filled (dry or liquid) medication vials 604, or ampoules 605, corresponding diluent(s) (if applicable) 702, hypodermic needles 403, and the pre-calibrated syringes 400 for the medication contained by the kit.
- FIG. 8 illustrates a pre-calibrated syringe barrel 402 according to embodiments of the present invention.
- the syringe barrel comprises measuring indicia 100 that correspond to dosages based on a patient's weight 103 or BSA (not shown). Measuring indicia 100 may appear on the inner surface and/or outer surface of the barrel 401, or the barrel may be manufactured to position the indicia at a pre-selected distance located between the inner and outer surface of the barrel 402, or any combination thereof as desired.
- the syringe barrel 402 comprises an internal core diameter 801 and an outer diameter 800, both of which may be adjusted through desired and pre-selected design features and manufacturing.
- the outer diameter 800 may be dimensioned to be consistent with industry standard dimension, thus enabling the syringe user to have the dexterity of an accepted, larger diameter barrel syringe (such as, for the preparation and administration of medication), as well as better visibility, particularly for smaller volume injections, and visibility of the corresponding indicia.
- FIG. 9 illustrates an industry standard 3 ml syringe 900.
- the syringe 900 comprises a plunger 901, a syringe barrel 902, and a needle 903, or sharp.
- Measuring indicia 904 may appear on the inner surface, outer surface of the barrel 902, or the barrel may be manufactured to position the indicia at a pre-selected distance located between the inner and outer surface of the barrel 902, or on any combination of surfaces thereof.
- the measuring indicia preferably correspond to the volume 905 of the syringe.
- Plunger 901 comprises a gasket 906 at one end of plunger 901.
- the gasket 906 is preferably a rubber piston gasket that indicates the volume within the syringe barrel 902.
- the internal diameter 907 and the outer diameter 908 of the syringe barrel 902 may be manufactured to industry standard sizes.
- FIG. 10 shows a pre-calibrated syringe 400 according to embodiments of the present invention.
- Syringe 400 comprises a plunger 401, a syringe barrel 402 and a needle 403.
- Syringe barrel 402 comprises measuring indicia 100 that may appear on the inner surface, outer surface of the barrel 402, or the barrel may be manufactured to position the indicia at a pre-selected distance located between the inner and outer surface of the barrel 402, or on any combination of surfaces thereof.
- Plunger 401 comprises a gasket 404 at one end of plunger 401.
- the gasket 404 is preferably a rubber piston gasket that indicates the volume within the syringe barrel 402.
- the internal, or core diameter 801 and the outer diameter 800 of the syringe barrel 402, both may be adjusted though desired and pre-selected design features and manufacturing.
- the outer diameter 800 may be dimensioned to be consistent with industry standard dimension, thus enabling the syringe user to have the dexterity of an accepted, larger diameter barrel syringe (such as, for the preparation and administration of medication) as well as better visibility, particularly for smaller volume injections, and visibility of the corresponding indicia.
- the syringe may be volumetrically calibrated and its indicia adjusted for the dosage strength of the particular medication that is appropriate for a patient in a specific weight range, m 2 , or dosage range. This allows clearer and more gradient-correlated dosage-to-weight or BSA (m 2 ) calibrated indicia for precise dosages than standard non- calibrated industry syringes (See FIG. 9).
- This feature permits volumes to be calibrated and measured in a smaller, more precise, gradient indicia scale for lower incremental doses, such as dosages for infants, pediatric patients, and other patients who are unusually sensitive to the medication as well as for the injection of extremely potent and dangerous medications such as pain management, anesthetics, biologies and oncology drugs than standard non-calibrated industry syringes (See FIG. 10).
- the syringe may also offer a fluorescent (or other colored) rubber piston gasket at the plunger tip, whereby maximum visual accuracy is obtained in preparing and verifying the dosage per calibration scale. (See FIG. 4, feature 404).
- FIGs 1-3 Further embodiments of the present invention allow the user to see the dosage of the subject medication in a singular calibrated measurement indicia that specifically correlates to another calibrated measurement indicia corresponding to the patient's weight or other characteristic(s), etc. (See FIGs 1-3).
- FIGs 1-3 Further embodiments of the present invention also offer a calibrated measurement indicia for a manufacturer's maximum suggested dosage of a subject medication that also specifically correlates to another calibrated measurement indicia corresponding to the patient's weight or other characteristic(s). (See FIGs 1-3).
- the syringes of the present invention may also bear additional separate pre-calculated measurement indicia specifically designed for a subject medication that enables the user to verify that he or she is administering the correct dosage. (See FIGs. 1-3).
- the present invention substantially eliminates risk of human error associated with computations ordinarily conducted by healthcare professionals relative to performing dosage-to-patient weight or BSA calculations, provided the user follows the pre- calibrated indicia on the syringe. This, in turn, eliminates the primary cause of Medical Administered Errors (MAE) for injected medications.
- MAE Medical Administered Errors
- the pre-packaged combinatorial kit of the present disclosure containing a reconstitutable medication, the corresponding diluent(s), and the pre-calibrated syringe(s) for the medication and diluent(s) within the kit, substantially eliminates multiple methods and procedures that are the leading direct cause of MAE from an injectable
- the combination kit substantially completely eliminates vital user procedures and methods ordinarily conducted by healthcare professionals, specifically: the collection of the correct medication for patient and patient class, the correct corresponding diluent(s) for particular medication, the correct diluent(s), syringe and needle for the particular route of administration, the correct calculation, measurement and procedures for the correct reconstitution of the medication by the diluent(s), the calculation determination of dosage-to-patient weight or BSA, and the subsequent verification of these procedures prior to the injection.
- the removal of these procedures and methods substantially eliminates the risk of human error associated with them. This, in turn, substantially eliminates the primary causes of Medical Administered Errors ("MAE”) for injected medications. (See FIG 7).
- MAE Medical Administered Errors
- the pre-packaged combinatorial kit of the present disclosure containing a medication in solution form, and the pre-calibrated correlating syringe(s) for the medication within the kit substantially eliminates multiple methods and procedures that are the leading direct cause of MAE from an injectable administration.
- the combination kit substantially completely eliminates vital user procedures and methods ordinarily conducted by healthcare professionals, specifically: the collection of the correct medication for patient class, the syringe and needle for the particular route of
- MAE Administered Errors
- the pre-packaged combinatorial kit containing a reconstitutable medication, the corresponding diluent(s) for the reconstitution(s), and the pre-calibrated syringe for the medication within the kit may yet further eliminate additional industry standard procedural user steps and methods including: research, calculations, measurements and verifications for the correct volume of diluent(s) necessary for the correct reconstitution(s) of the medication within the vial.
- the diluent(s) within the kit is volumetrically specifically calibrated to offer the correct dilution of the medication within the kit. The user needs only to withdraw the diluent completely from the vial or ampoule and then to completely inject that volume into the vial of the medication, thus eliminates multiple methods and procedures that are direct causes of MAE from an injectable administration.
- the pre-packaged combinatorial kit containing a reconstitutable medication may also have a calibrated syringe for the diluents(s) within the kit that would provide specific indicia to provide the proper withdrawal of the diluent into the diluent syringe for the subsequent correct procedures and methods for the reconstitution of the medication within the kit.
- the pre-packaged combinatorial kit may contain one of more syringes or needles for the syringes.
- Embodiments of the present disclosure substantially reduce the cost associated with having healthcare providers prepare, collect, and correlate the correct components for the medicinal injection for a particular patient because the present invention eliminates the need for a healthcare provider to perform these functions and the need for the calculation to then be verified, and the administration authorized, by a supervisor or other healthcare provider.
- Variations of the present disclosure may substantially reduce a heath care institution's liability insurance costs by reducing and/or eliminating MAE that result from the injection of medications and also by implementing a more sophisticated passive safety system, and methods and apparatus than typical industry standard practices
- measurement indicia on the syringe offers crucial double or triple visual re-confirmations, including, for example, dosage to patient weight or BSA, name of medication, recommended dosage to weight and/or maximum dosage per weight, allowing the user to perform last-minute safety checks, and thereby discontinue or revise the dosage while preparing or even administering the medication.
- These enhanced visual aids further prevent incorrect or over-dosage of the patient even at the last stages of the
- the internal core diameter of the syringe barrel may be reduced to enable holding smaller volumes of the medication in a thinner barrel (a barrel having a reduced diameter), thereby making the measurement indicia more precise.
- a smaller core diameter makes it possible for the medication to be further disbursed in the syringe barrel, thus effectively extending the volume of the medication further into the syringe barrel.
- the calibrated volume in the barrel enables the dosage-to-patient- weight-calibrated measurement indicia to be visually enhanced by expanding the measurement indicia into a larger elongated scale and thus also offering more precise and lower graduated measurement increments. This visual enhancement will also help ensure the administration accuracy for smaller, more precise doses, such as, for example, doses for pediatric patients, etc. (See FIGs. 9 and 10).
- the internal core diameter of the syringe barrel may be adjusted by through various design features, yet the exterior diameter of the syringe barrel may not be adjusted, enabling the user to have the dexterity and/or better visibility of a larger diameter barrel syringe for the preparation and administration. (See FIGs. 8 and 9.)
- Another embodiment of the disclosure is directed to a vial or ampoule or other container containing a pre-determined volumetric measurement of a specific medication that would specifically correlate to the dosage-to-weight or dosage-to-BSA calibrated measurement indicia on the syringe. This pre-determined amount could then be loaded into the syringe at the time the medication is administered to the patient. Accordingly, in this embodiment, there would be no calculations or correlations necessary for the user to load the syringe from the vial or ampoule or other container to the correct dosage of the medication to the patient's weight for administration.
- Additional embodiments contemplate allowing the dosage to patient weight calibrated measurement indicia on the syringe to uniquely target specific weight scales, customized for adult, pediatric, or infant weight, etc.
- the calibrated measurement indicia scale would thereby allow better visibility as it is specifically focused on a particular weight and patient range allowing for more accurate incremental dosages and less over all waste through this volume-scaled patient range calibration. (See FIG. 6).
- Embodiments of the present disclosure consist of a single -use syringe that is pre- filled at the time of manufacture with a pre-determined volume of a particular medication.
- the specific dosage of the subject medication could then be administered according to the syringe's calibrated measurement indicia that is pre-calculated based on the weight of the patient or BSA and the correlating dosage. It further allows the user to see the dosage of the subject medication in one calibrated measurement indicia that specifically correlates to another calibrated measurement indicia corresponding to the patient's weight or BSA.
- the syringe may come in a combination kit containing a separate pre-filled (either dry or liquid) vial or ampoule injectable medication that is specifically volume-scaled to solely correlate with the syringe's volumetric design and calibrated measurement indicia. (See FIG. 6).
- the syringe could be loaded and administered without the need for any calculations of the subject medication to patient weight.
- the syringe would also be a "ready-to-fill" syringe that would have various preselected indicia stamped on it including, for example, the name of medication, strength of medication and the dosage strength-to-patient weight, etc. (See FIGs 4-7).
- the syringe may come in a combination kit containing a separate pre-filled dry vial injectable medication with a corresponding vial or ampoule of diluent for reconstitution of the dry vial injectable medication into a solution.
- Both the dry powder vial of the injectable medication and the corresponding diluent are also specifically volume-scaled to solely correlate each other with the syringe's volumetric design and calibrated measurement indicia.
- the diluent would be completely extracted by the syringe from the diluent vial or ampoule, thereby eliminating the need for measurement or calculation and then completely injected into the dry powder vial of the injectable medication for the reconstitution of the powder into a solution.
- the injectable medication then is extracted out of the vial with the syringe according to the proper weight indicia on the syringe, and then medication is administered to the patient. All of these steps substantially eliminate the need for calculations or correlations of the medication's reconstitution and the calculation of the subject medication to patient weight based upon the unique pre-calibration and correlation of the invention itself. (See FIG. 7).
- the syringe plunger in both versions, pre-filled and ready to fill may be substantially permanently stamped with one or more identifying
- the present disclosure's syringe indicia therefore addresses and prevents two of the most common MAE's plaguing the health care industry, namely: 1) wrong dosage, and 2) wrong medication.
- embodiments of the present disclosure eliminate the need for a user to calculate the dosage strength of medication (meg, cc, iu, mg, ml) to corresponding patient weight or BSA (G, KG, LB, m ).
- the re-verification safety check calibration indicia that appear on the syringe provide users with several key visual aids to avoid, for example, administration errors in the dosage of the medication, the medication itself and the strength of the medication, etc. (See FIG. 5).
- the syringe plunger comprises a clear and conspicuous substantially permanent indication of at least the medication name, dosage strength and recommended dosage to weight of the medication that it contains. (See FIGs. 4 and 5).
- measurement indicia offer a clear indication of dosage in a column dedicated to MCG, CC, IU, MG, ML, and then substantially simultaneously further offers a clear conversion of the correlating figure in a G, KG, LB, utilizing the recommended manufacturer's dosage schedule in another parallel column (See FIGs. 1-3).
- the embodiments of the present invention substantially minimize the risk of human error in the administration of injectable medication to a greater degree than any other design presently known.
- the user does not have to calculate the appropriate dosage for the individual patient weight to load the syringe from a vial or ampoule or administer the medication.
- the user must simply follow the syringe's indicia and load and inject, or in the case of a pre-filled syringe, inject the medication according to the designed patient weight indicia.
- embodiments of the present disclosure may be used for all drug applications, dry fill vial, lyophilized vial, liquid vial, ampoule, and prefilled injection, without a variation in any way from the original manufacturer-indicated administration of the injectable medication or the manufacturer's original regulatory stability approved packaging.
- embodiments of the present disclosure substantially eliminate the need for complicated color coding, additional containers, calibration, conversion, additional equipment, drug components, further calculations, open or reusable drug products, cleaning and sterilization of any equipment or components, etc. This is because the alternatives of the present disclosure bear indicia that are pre-calibrated to the specific medication for which it is intended. The user is therefore not required to perform any further calibrations or calculations.
- Embodiments of the present disclosure offers health professionals, multiple, clear and available visual verification features and re- verification features to prevent MAE's that other syringes and devices currently on the market lack.
- a syringe in both pre-filled and ready-to-fill versions, will be permanently stamped with the name of the medication, dosage strength of medication and recommended dose-to-weight on the plunger, thereby helping to prevent the administration of the wrong medication and/or wrong dosage strength of the medication to the patient.
- Known syringes do not bear this information.
- a syringe in both pre- filled and ready versions will permanently bear the dosage strength of the medication contained therein on the plunger. See FIG. 4. This will further prevent users from administering the wrong dosage of the medication. Known syringes do not bear this conspicuous information on the plunger.
- MCG, MG, ML, IU, CC volume strength
- BSA BSA
- the user does not need to perform any calculations to determine the proper dosage.
- the user must merely know the weight or BSA of the patient and then use the syringe designed for a patient of such weight range.
- embodiments of the present disclosure that are intended for a specific targeted patient group by volumetric adjusting the syringe's volume capacity and the calibrated measurement indicia to a targeted patient weight group.
- volumetric adjusting the syringe's volume capacity and the calibrated measurement indicia to a targeted patient weight group In the case of pediatric or infant injectables, a major issue stems from a typical volume syringe with a large calibration scale for adults. In most cases, it is much more difficult to accurately prepare smaller doses than if the volume and the syringe was downsized and thus the scale specifically pre-adjusted to that particular patient weight scale (0.5 KG to 10.0 KG in MCG or MG, etc.). (See FIGs. 6-10).
- the barrel of the syringe may offer two or three or more calibrated measurement indicia.
- the medication contained therein will be measured by volume dosage (MCG, MG, CC, ML, IU strength).
- MCG volume dosage
- MG volume dosage
- CC volume dosage
- ML volume dosage
- IU volume dosage
- BSA volume dosage
- a direct correlation to corresponding patient weight or BSA G, KG, LB or m
- the barrel of the syringe may offer a third calibrated measurement indicia column providing yet another correlation in grams, kilograms, pounds or m that would indicate the maximum dosage schedule for that patient weight or BSA.
- either or all three columns in the calibration scale on the syringe could be clear or color tinted (for example, yellow for recommended dose and red for maximum dose, etc.). (See FIGs 1-3).
- the syringe may be pre-filled ready for injection or within a pre-determined kit containing
- volumetrically pre-calibrated vials or ampoules which would require no calculations or correlations for the subject medication dosage amount verses weight of patient. This substantially eliminates the risk of human error inherent in known systems, methods and apparatuses.
- the downsizing of a single dose vial or ampoule to an individual kit for pediatric creates a cost savings by avoiding the tremendous waste associated with discarding the unused remainder of a vial or ampoule of medication that occurs when known syringes are used for reduced dosages.
- the re -use of single use vials is a major health contamination problem in the health care industry worldwide today.
- the downsizing of a single dose vial or ampoule to an individual kit for pediatric or other reduced volume dosage reduces the possibility of re -use of a single use vial based upon the end user not wanting to through away such an excess volume of the product.
- the reduced dosage also could limit the severity of an over dosage based upon the reduced medication volumes. (See FIGs. 6-7).
- the combination kit of the embodiments of the present disclosure preferably comprise a calibrated vial or ampoule of medication with a pre-calibrated syringe with corresponding calibrated diluent(s), (if applicable, antiseptic wipes) and is preferably packaged as a single unit in a tamper resistant package and may also comprise an instructional pamphlet for the particular administration of medication, thus consolidating all the necessary components for the injection in one combination kit.
- No known syringe or means for administering injectable medication offers the level of safety and simplicity that the present invention provides. (See FIG. 7).
- Embodiments of the present disclosure would not need additional components, combinations of components, equipment, precautionary methods, product education, instruction, sterilization, cleaning, replacement parts, nor additional stability or regulatory approvals, as are required for known devices deemed to aid and prevent MAE. Further, the present disclosure would not need a complex color coding which would require education of staff, complex procedures, additional human calculation, combinatory methods, etc. that would increase the likelihood of human error and, in the end, result in increased MAE.
- Embodiments of the present disclosure would not rely on a safety platform based upon a printed sticker or a hand- written sticker or other mark or calibration that would be placed on the syringe or other apparatus to supply the necessary data for name, strength and dosage or other necessary information for the drug to be administered correctly. These features are necessary under presently known regimens. Placement of a sticker, mark calculation, or other mechanism or device indicating this data relies on human calculation and combinatory methods, as well the accuracy of the medical professional placing the data sticker on the syringe and the correct syringe.
- the placement of a sticker or other type of placard still does prevent an MAE based on one of the most common MAE; an overdose or under dose of the drug due to improper calculation or misreading the calibration scale of the syringe when it is being administered by a health care professional.
- Some known devices seek to create a system under which multiple drugs could be injected through a single syringe with a standard, "one fits all” calibration in multiple weights, height, age, etc.
- the non-drug specific syringe with these pre-determined calibrations is then placed in multi-drug containment systems that will "store” the drug products until syringe distribution.
- These containment systems would allow the syringe to withdraw the drug product to the pre-calibrated measurements on the syringe for the syringe then to be readied for injection. This creates a substantial risk of human error.
- the medication be opened and drawn into the syringe, then injected out of its regulatory manufacturers' approved packaging only to be re-loaded and then injected into the patient, adding multiple human (relied upon) steps, and actually increasing the likelihood of a MAE.
- the known administration systems often deviate from the manufacturer's recommended administration of the drug, and industry regulations regarding removing pharmaceutical product, especially a pyrogen free injectable, out of its regulated intended packaging. Indeed, such injectables should not be held in any other packaging other than the manufacturer's original packaging. Only the manufacturer's packaging has undergone stability studies specifically for those finished dosage formulations and received medical device approvals for the distribution of the individual medicines it deems to handle.
- injectable medications including oncology medications, are highly toxic or cytotoxic. It is crucial that they be exposed only in a controlled environment. If they are removed from their approved packaging, exposed to open air, and aerosolized, they can be extremely hazardous to the healthcare providers who are handling them.
- any additional containers or containment systems would need to be tested for endo-toxin levels to ensure sterility or be disposed of after each use prior to being refilled.
- known syringes with containment devices do not eliminate risk of MAEs by because they do not reduce the potential for human error. Instead, they increase the likelihood of MAE by increasing the need for multiple hands-on methods, procedures, steps and storage.
- a typical single use vial may be in a 500 Mg vial, or a 100 Mg Ampoule (See FIG. 6, feature 601).
- a specific pediatric dosage for that drug is 5 mg/Kg. This would result in a typical pediatric patient weighing less than 40 kg (approximately 88 pounds) to require a dosage (according to recommended dosage schedule) of less than 200 mg. As a result, over half of the vial will be discarded and wasted, (this at the maximum patient body weight of 40 kg; all weights under 40 kg would only increase the waste). (See FIGs. 6 and 6A).
- a pediatric dosage can be scaled for 0.5 kg to 8.0 kg (Fig. 6A, feature 606).
- Fig. 6A, feature 606 over 460 mgs of a 500 mg vial and 60 mg of a 100 mg vial would be wasted with current injection technology. There would be no waste using the present invention.
- the syringe calibration indicia of the present invention could also be enlarged to effectively offer better visibility and more precise incremental indicia, (for example in MCG). This is made possible by the volumetric predesigned aspects of the present invention and product downsizing correlating to the present disclosure.
- Embodiments of the present disclosure also allow for the scaled volume individualization of pre-filled syringes.
- a leading typical single use pre-filled syringe (PFS) for a popular anesthetic is, for example, in a 50 mg PFS which would be used for the initial (loading) dosage at a rate of 0.5-1 mg/Kg. Therefore a 50 mg, prefilled syringe would offer enough product suitable or a dosage for a patient of up to 50 kg (110 lb) or to 100 kg (220 lb). This is the minimum size available.
- a pediatric device could be scaled for 1 kg to 20 kg in a 20 mg embodiment of the present invention.
- the reduced scaled volume of the drug could also decrease the size of the overdose and, as a result, the severity of the MAE and adverse event.
- the syringe calibration indicia also could be enlarged to effectively offer better visibility and more precise indicia, (for example in MCG), by the volumetric predesigned aspects of the syringe and product downsizing for the syringe.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13703673.7A EP2806924A1 (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
CA2862633A CA2862633C (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
MX2017012034A MX384129B (en) | 2012-01-27 | 2013-01-24 | SAFETY DOSE COMBINATION KIT AND SAFETY SYRINGE. |
MX2014009038A MX351045B (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit. |
CN201380014750.8A CN104168939A (en) | 2012-01-27 | 2013-01-24 | Safety Syringes and Safety Doses Combo Kit |
BR112014018520A BR112014018520A8 (en) | 2012-01-27 | 2013-01-24 | safety syringe and safety dose combination kit |
JP2014554822A JP6195577B2 (en) | 2012-01-27 | 2013-01-24 | Syringe with enhanced safety and combination kit for safe drug administration |
AU2013222819A AU2013222819B2 (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
EP19217539.6A EP3653243A1 (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
HK15100308.0A HK1199849A1 (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
AU2016269509A AU2016269509B2 (en) | 2012-01-27 | 2016-12-08 | Safety syringe and safety dose combination kit |
AU2018232988A AU2018232988B2 (en) | 2012-01-27 | 2018-09-20 | Safety syringe and safety dose combination kit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591683P | 2012-01-27 | 2012-01-27 | |
US61/591,683 | 2012-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013126173A1 true WO2013126173A1 (en) | 2013-08-29 |
Family
ID=47684036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/022926 WO2013126173A1 (en) | 2012-01-27 | 2013-01-24 | Safety syringe and safety dose combination kit |
Country Status (11)
Country | Link |
---|---|
US (4) | US9192723B2 (en) |
EP (2) | EP2806924A1 (en) |
JP (1) | JP6195577B2 (en) |
CN (2) | CN111790018A (en) |
AU (3) | AU2013222819B2 (en) |
BR (1) | BR112014018520A8 (en) |
CA (2) | CA3006218C (en) |
HK (1) | HK1199849A1 (en) |
MX (2) | MX384129B (en) |
TW (1) | TW201343214A (en) |
WO (1) | WO2013126173A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2011094C2 (en) * | 2013-07-04 | 2015-01-06 | Vlow Medical B V | Syringe with alternatively selectable graduations. |
WO2015034870A3 (en) * | 2013-09-03 | 2015-06-04 | Arocha Max | Double-chamber mixing syringe and method of use |
JP2017516561A (en) * | 2014-05-28 | 2017-06-22 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Dose labeling mechanism for drug delivery device and drug delivery device |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11617835B2 (en) | 2012-02-01 | 2023-04-04 | Cd Acquisitions, Llc | Apparatuses, methods, and systems for delivering measured doses of medication |
CA2863073C (en) | 2012-02-01 | 2021-04-27 | Certa Dose, Inc. | System for delivering medication |
EP2908892A1 (en) | 2012-10-22 | 2015-08-26 | Michael A. Creaturo | Apparatus and method for mixing a medicament and supplying it to an intravenous fluid |
US9867947B2 (en) * | 2013-08-22 | 2018-01-16 | Nicholas Appelbaum | Label for a syringe |
MX2016003141A (en) * | 2013-09-11 | 2016-11-14 | Parenteral Tech Llc | Measurement indicia syringe sleeve and syringe needle retraction mechanism. |
US20150231335A1 (en) * | 2013-09-11 | 2015-08-20 | Parenteral Technologies, Llc | Measurement indicia syringe sleeve and syringe needle retraction mechanism |
US9271896B2 (en) * | 2014-06-21 | 2016-03-01 | David Clements | Apparatus for weight based single doses of medication |
WO2016081069A1 (en) * | 2014-11-21 | 2016-05-26 | Medirect, Pllc | Weight based pediatric syringe system |
US9474864B2 (en) | 2014-12-15 | 2016-10-25 | Brell Medical Innovations, LLC | Safety syringe and methods for administration of a medicament dose by subject weight |
USD938023S1 (en) | 2015-09-02 | 2021-12-07 | Certa Dose, Inc. | Drug delivery syringe |
US9566388B1 (en) * | 2016-04-05 | 2017-02-14 | Corey Dewayne Jones | Syringe measurement marking and dosing system |
EP3453417A4 (en) * | 2016-04-25 | 2020-03-04 | Terumo Kabushiki Kaisha | Syringe barrel and pre-filled syringe |
EP3454924A4 (en) | 2016-05-11 | 2020-04-15 | Certa Dose, Inc. | RADIOLOGICAL DOSING SYSTEM AND METHOD |
JP6729149B2 (en) * | 2016-08-04 | 2020-07-22 | ニプロ株式会社 | Syringe and prefilled syringe |
US10881803B2 (en) * | 2016-10-03 | 2021-01-05 | William T. MCCLELLAN | System and method to store, load and administer a compound via an ampule |
US11246989B1 (en) | 2017-01-10 | 2022-02-15 | Nicholas William Halbach | Small syringe with enhanced readability |
US11783933B2 (en) | 2017-02-23 | 2023-10-10 | Smiths Medical Asd, Inc. | Device with identifier |
WO2019075396A1 (en) | 2017-10-12 | 2019-04-18 | Leslie Tufts | Method and apparatus for injecting a neurotoxin into a localized area |
WO2019144151A1 (en) * | 2018-01-19 | 2019-07-25 | Certa Dose, Inc. | Rapid medication delivery system and method resistant to overdosing |
GB2570706B (en) * | 2018-02-05 | 2020-10-14 | Innovative Tech Ltd | A banknote validator |
US11712522B2 (en) | 2018-05-01 | 2023-08-01 | CD Acquistions, LLC | System and method for sequential delivery of measured doses of medication |
WO2019222625A1 (en) | 2018-05-17 | 2019-11-21 | Certa Dose, Inc. | Syringe holder for medication dosing |
WO2020132414A1 (en) * | 2018-12-20 | 2020-06-25 | Parenteral Technologies, Llc | Integrated container and dosing device for liquid medication delivery |
USD943737S1 (en) | 2019-01-22 | 2022-02-15 | Certa Dose, Inc. | Overdose resistant drug delivery syringe |
WO2020167858A1 (en) * | 2019-02-11 | 2020-08-20 | Certa Dose, Inc. | Multiple condition dosing system |
US11833336B2 (en) * | 2019-02-19 | 2023-12-05 | Nancy C. Stamps | Syringe and kit for administering predetermined specific epinephrine doses |
USD894381S1 (en) * | 2019-03-29 | 2020-08-25 | Retractable Technologies, Inc. | Syringe barrel |
US11907029B2 (en) | 2019-05-15 | 2024-02-20 | Upstream Data Inc. | Portable blockchain mining system and methods of use |
US11439760B2 (en) | 2019-07-14 | 2022-09-13 | Nilesh Parikh | Syringes |
CA3076653A1 (en) | 2020-03-21 | 2021-09-21 | Upstream Data Inc. | Portable blockchain mining systems and methods of use |
EP3998094A4 (en) * | 2020-08-25 | 2022-09-07 | Eoflow Co., Ltd. | Liquid medicine injection device |
USD1043739S1 (en) | 2021-11-01 | 2024-09-24 | Caleb Hernandez | Display screen or portion thereof with graphical user interface |
USD1043740S1 (en) | 2021-11-01 | 2024-09-24 | Caleb Hernandez | Display screen or portion thereof with graphical user interface |
CN113911993B (en) * | 2021-11-12 | 2023-03-21 | 临沂宏康食品有限公司 | Veterinary medicament variable filling device |
US12092486B2 (en) | 2021-12-14 | 2024-09-17 | The Esab Group Inc. | Flow gauge and flow gauge scale assembly |
NL2031567B1 (en) * | 2022-04-13 | 2023-11-03 | Sjj Solutions B V | Syringe assembly with marking on plunger for dosing |
DE112023002585T5 (en) * | 2022-06-07 | 2025-03-27 | Thomas Webb | A botulinum toxin injection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2432605A (en) * | 1944-03-01 | 1947-12-16 | Joseph H Barach | Graduated receptacle for syringes |
US20020088131A1 (en) * | 1999-10-08 | 2002-07-11 | Baxa Ronald Dale | Syringe dose identification system |
US20040024368A1 (en) * | 2002-08-02 | 2004-02-05 | Broselow James B. | Color-coded medical dosing container |
WO2004069314A1 (en) * | 2003-02-04 | 2004-08-19 | Novo Nordisk A/S | Injection device with rotatable dose setting |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5971638U (en) * | 1982-11-04 | 1984-05-15 | 塩野義製薬株式会社 | vial |
US20020010429A1 (en) * | 1989-08-04 | 2002-01-24 | Grogan Jack Raymond | Dose by weight medicine dropper |
US20090264815A1 (en) * | 1989-08-04 | 2009-10-22 | Grogan Jr Jack Raymond | Dose calculating dispenser using a body weight scale on a medicine dropper |
US20040024372A1 (en) | 1989-08-04 | 2004-02-05 | Grogan Jack Raymond | Dose by weight medicine dropper |
JP3146616B2 (en) * | 1992-04-01 | 2001-03-19 | 株式会社ニッショー | Dry formulation dissolution kit |
US6132416A (en) * | 1998-09-01 | 2000-10-17 | Broselow; James B. | Universal medication dosing system |
US6413241B1 (en) | 2000-03-31 | 2002-07-02 | Science & Technology Corporation @Unm | Per kilo doser |
JP2001305333A (en) * | 2000-04-26 | 2001-10-31 | Dainippon Printing Co Ltd | Color filter and liquid crystal display device |
US6904867B2 (en) * | 2001-06-25 | 2005-06-14 | David B. Zamjahn | Calculated dose medicine dispenser |
US20040186437A1 (en) * | 2003-03-20 | 2004-09-23 | Frenette Claude E. | Content-coded medical syringe, syringe set and syringe content identification method |
USD545429S1 (en) * | 2004-11-15 | 2007-06-26 | Hays Janet C | Calibrated medicine dispensing apparatus |
DE102007026083A1 (en) * | 2007-05-25 | 2008-11-27 | Haselmeier S.A.R.L. | injection device |
JP2007275609A (en) * | 2007-05-25 | 2007-10-25 | Eisai R & D Management Co Ltd | Syringe |
US7918830B2 (en) * | 2007-12-03 | 2011-04-05 | Pharmedium Services, Llc | Safety device for drug delivery devices and containers |
GB2461013A (en) * | 2007-12-18 | 2009-12-23 | Asrar Rashid | Vessel with gradations marked thereon relating to a physical characteristic of a patient |
US20090185973A1 (en) * | 2008-01-22 | 2009-07-23 | Adenobio N.V. | Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
GB2458126A (en) * | 2008-03-04 | 2009-09-09 | Patrick Davies | A vessel having gradations relating to specific measurements |
US8361055B2 (en) * | 2008-11-25 | 2013-01-29 | Tucker Peter L | Syringe and method for reconstitution of dry-form drugs and medicines |
JP3149156U (en) * | 2008-12-26 | 2009-03-12 | テルモ株式会社 | Prefilled syringe and drug administration kit |
CN201618244U (en) * | 2010-03-03 | 2010-11-03 | 中国人民解放军第四五一医院 | Special-purpose syringe for common insulins |
-
2013
- 2013-01-24 CA CA3006218A patent/CA3006218C/en active Active
- 2013-01-24 US US13/748,859 patent/US9192723B2/en active Active
- 2013-01-24 CN CN202010590050.5A patent/CN111790018A/en active Pending
- 2013-01-24 TW TW102102585A patent/TW201343214A/en unknown
- 2013-01-24 MX MX2017012034A patent/MX384129B/en unknown
- 2013-01-24 BR BR112014018520A patent/BR112014018520A8/en not_active Application Discontinuation
- 2013-01-24 WO PCT/US2013/022926 patent/WO2013126173A1/en active Application Filing
- 2013-01-24 AU AU2013222819A patent/AU2013222819B2/en active Active
- 2013-01-24 EP EP13703673.7A patent/EP2806924A1/en not_active Ceased
- 2013-01-24 EP EP19217539.6A patent/EP3653243A1/en active Pending
- 2013-01-24 MX MX2014009038A patent/MX351045B/en active IP Right Grant
- 2013-01-24 CA CA2862633A patent/CA2862633C/en active Active
- 2013-01-24 HK HK15100308.0A patent/HK1199849A1/en unknown
- 2013-01-24 CN CN201380014750.8A patent/CN104168939A/en active Pending
- 2013-01-24 JP JP2014554822A patent/JP6195577B2/en active Active
-
2015
- 2015-10-07 US US14/877,349 patent/US9987430B2/en active Active
- 2015-10-23 US US14/921,325 patent/US9750883B2/en active Active
-
2016
- 2016-12-08 AU AU2016269509A patent/AU2016269509B2/en active Active
-
2018
- 2018-05-24 US US15/988,461 patent/US10857299B2/en active Active
- 2018-09-20 AU AU2018232988A patent/AU2018232988B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2432605A (en) * | 1944-03-01 | 1947-12-16 | Joseph H Barach | Graduated receptacle for syringes |
US20020088131A1 (en) * | 1999-10-08 | 2002-07-11 | Baxa Ronald Dale | Syringe dose identification system |
US20040024368A1 (en) * | 2002-08-02 | 2004-02-05 | Broselow James B. | Color-coded medical dosing container |
WO2004069314A1 (en) * | 2003-02-04 | 2004-08-19 | Novo Nordisk A/S | Injection device with rotatable dose setting |
Non-Patent Citations (2)
Title |
---|
NATIONAL VITAL STATISTICS REPORTS., vol. 47, no. 25, 1999, pages 6 |
See also references of EP2806924A1 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2011094C2 (en) * | 2013-07-04 | 2015-01-06 | Vlow Medical B V | Syringe with alternatively selectable graduations. |
EP2821089A1 (en) * | 2013-07-04 | 2015-01-07 | VLOW Medical B.V. | Syringe with alternatively selectable graduations |
US9566387B2 (en) | 2013-07-04 | 2017-02-14 | Vlow Medical B.V. | Syringe with alternatively selectable graduations |
WO2015034870A3 (en) * | 2013-09-03 | 2015-06-04 | Arocha Max | Double-chamber mixing syringe and method of use |
US10420888B2 (en) | 2013-09-03 | 2019-09-24 | Max Arocha | Double-chamber mixing syringe and method of use |
JP2017516561A (en) * | 2014-05-28 | 2017-06-22 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Dose labeling mechanism for drug delivery device and drug delivery device |
US10973980B2 (en) | 2014-05-28 | 2021-04-13 | Sanofi-Aventis Deutschland Gmbh | Dose indicating mechanism for a drug delivery device and drug delivery device |
Also Published As
Publication number | Publication date |
---|---|
EP2806924A1 (en) | 2014-12-03 |
MX2014009038A (en) | 2015-02-24 |
AU2016269509B2 (en) | 2018-09-13 |
US10857299B2 (en) | 2020-12-08 |
AU2018232988B2 (en) | 2019-02-28 |
MX351045B (en) | 2017-09-27 |
AU2013222819A1 (en) | 2014-08-21 |
US20180264197A1 (en) | 2018-09-20 |
CN111790018A (en) | 2020-10-20 |
JP2015508321A (en) | 2015-03-19 |
AU2016269509A1 (en) | 2017-01-05 |
US9750883B2 (en) | 2017-09-05 |
CA2862633C (en) | 2018-07-24 |
BR112014018520A8 (en) | 2019-12-03 |
AU2018232988A1 (en) | 2018-10-18 |
TW201343214A (en) | 2013-11-01 |
HK1199849A1 (en) | 2015-07-24 |
US9192723B2 (en) | 2015-11-24 |
CA3006218C (en) | 2021-08-24 |
CA2862633A1 (en) | 2013-08-29 |
CN104168939A (en) | 2014-11-26 |
JP6195577B2 (en) | 2017-09-13 |
EP3653243A1 (en) | 2020-05-20 |
CA3006218A1 (en) | 2013-08-29 |
US20160022913A1 (en) | 2016-01-28 |
US20130204225A1 (en) | 2013-08-08 |
AU2013222819B2 (en) | 2017-02-02 |
US9987430B2 (en) | 2018-06-05 |
US20160045671A1 (en) | 2016-02-18 |
MX384129B (en) | 2025-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018232988B2 (en) | Safety syringe and safety dose combination kit | |
US20240299252A1 (en) | Apparatuses, methods, and systems for delivering medication using medication kits | |
US9302050B2 (en) | Safety syringe and safety dose combination kit and methods | |
US9271896B2 (en) | Apparatus for weight based single doses of medication | |
JP7297446B2 (en) | Devices, methods and systems for delivering pharmaceuticals using medication kits | |
JP7579804B2 (en) | Medication system having stepped dosage markings | |
US20180043103A1 (en) | Syringes with improved locking units | |
US9302052B1 (en) | Pre-loaded syringe with metered dosing and methods of use | |
Cambruzzi et al. | Variation in syringes and needles dead space compared to the International Organization for Standardization standard 7886-1: 2018 | |
JP2021504095A (en) | Syringe with at least one radial outward extension panel | |
JP2012501197A (en) | Methods for standardizing injectable drugs and their diluents | |
JP6467064B2 (en) | Syringe | |
US10010378B2 (en) | Rapid sequence medical procedure tray | |
Taylor-Smith et al. | Oral analgesia pre-medication: a practice with multiple benefits | |
Cohen et al. | ISMP Medication Error Report Analysis-Distribute Instructions for Oral Dispenser; Seasonal Vaccine “H1N1” Is Not 2009 Pandemic Strain; Same Name, Different Drug; Confusion Between Organ Preservation Solutions and IV Containers; Enteral Nutrition Safety; LQ? LAR? DSC? Drug Name Suffixes and Their Meanings | |
BRIEFS | AUSTRALIAN INCIDENTS Look-alike sound-alike trade names: Seronia-Setrona | |
Hunnisett-Dritz | FDA recognition of first-world drug regulators as means of relieving US drug shortages | |
Azad et al. | Simplified Equations for Calculation of Highly Potent Intravenous Drug Infusion with Confidence-A Review Article | |
WO2016081069A1 (en) | Weight based pediatric syringe system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13703673 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2862633 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014554822 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/009038 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013703673 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013222819 Country of ref document: AU Date of ref document: 20130124 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014018520 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014018520 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140728 |